Rostaporfin

DB06659InvestigationalSmall molecule

Investigated for use/treatment in macular degeneration.

Chemical structure of Rostaporfin
Primary indication
Investigated for use/treatment in macular degeneration.Curator reviewed
Formula / weight
C37H42ClN4O2Sn · 728.93 g/mol (avg)

Resolves to

Compound
UNII466G63QE7GCAS284041-10-7
Structure
InChIKeyDMAHZCZCPVOYGS-ZLSDMPCXSA-LSMILES[Cl-].[Sn+4].CCOC(=O)C1=CC2=C3[N-]\C(=C/C4=N/C(=C\C5=C(CC)C(C)=C([N-]5)\C=C5/N=C2C(C)=C5CC)/C(C)=C4CC)[C@@H](C)[C@]13CC

What you can answer from here — as of July 03, 2026

4Drug interactionsStructured to mechanism, not free text
Sign in
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which companies are running trials of Rostaporfin, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In